Researchers have found that measuring the diversity of mutations within a tumour can more accurately predict the success of immunotherapy treatments. | Health
An MIT study reveals a possible explanation for why checkpoint blockade inhibitors don’t work well for some patients whose tumors have a high mutational burden.
MIT Koch Institute researchers develop a cancer treatment combining immune checkpoint blockade therapy with STING. The resulting vaccine eliminates most tumors and prevents recurrence in mice, with minimal side effects.
MIT researchers developed a way to deliver a stimulatory molecule called IL-12 directly to tumors, avoiding the toxic effects that can occur when immunostimulatory drugs are given throughout the body.